Production of the Subdomains of the Plasmodium falciparum Apical Membrane Antigen 1 Ectodomain and Analysis of the Immune Response

The apical membrane antigen 1 of Plasmodium falciparum is one of the leading candidate antigens being developed as a vaccine to prevent malaria. This merozoite transmembrane protein has an ectodomain that can be divided into three subdomains (D I, D II, and D III). We have previously expressed a maj...

Full description

Saved in:
Bibliographic Details
Main Authors: Lalitha, P V, Ware, Lisa A, Barbosa, Arnoldo, Dutta, Sheetij, Moch, J K, Haynes, J D, Fileta, Bader B, White, Charles E, Lanar, David E
Format: Report
Language:English
Subjects:
ANTIBODIES
ANTIGENS
ASSAYING
ERYTHROCYTES
GENES
GROWTH(PHYSIOLOGY)
IMMUNITY
IN VITRO ANALYSIS
MALARIA
Medicine and Medical Research
MEMBRANES(BIOLOGY)
MEROZOITES
Microbiology
Pharmacology
PLASMODIUM FALCIPARUM
PROTEINS
RABBITS
RESPONSE
RESPONSE(BIOLOGY)
VACCINES
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The apical membrane antigen 1 of Plasmodium falciparum is one of the leading candidate antigens being developed as a vaccine to prevent malaria. This merozoite transmembrane protein has an ectodomain that can be divided into three subdomains (D I, D II, and D III). We have previously expressed a major portion of this ectodomain and have shown that it can induce antibodies that prevent merozoite invasion into red blood cells in an in vitro growth and invasion assay. To analyze the antibody responses directed against the individual subdomains, we constructed six different genes that express each of the domains separately (D I, D II, or D III) or in combination with another domain (D I II, D II III, or D I III). These proteins were purified and used to immunize rabbits to raise construct-specific antibodies. We demonstrated that D I II induced a significant amount of the growth-inhibitory antibodies active in the growth and invasion assay. Pub. in Infection and Immunity, v72 n8, p4464-4470, Aug 2004. Prepared in cooperation with Walter Reed Medical Center, Washington, DC.